EMA Authorised: Vyepti (Eptinezumab) — H. Lundbeck A/S

View source ↗

Summary

The European Medicines Agency has authorised Vyepti (eptinezumab) by H. Lundbeck A/S for migraine disorders.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Migraine

Drugs mentioned

• VYEPTI (eptinezumab)

Snippet

Status: Authorised. Therapeutic area: Migraine Disorders. MAH: H. Lundbeck A/S. Decision date: 12/09/2024